"Levomepromazine"@en . "60-99-1"@en . "(-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine"@en . . . . "Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%."@en . . . . . . . . . . . . . . . . . . . . . . "Methotrimeprazine"@en . . "Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role. "@en . "approved"@en . "Symptoms of overdose include convulsions, spastic movements, and coma."@en . . "Levomepromazina"@en . "# \"Link\":http://www.doctissimo.fr/medicament-NOZINAN.htm"@en . . "(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine"@en . "Methotrimeprazine"@en . . . "Humans and other mammals"@en . . . . . . " "@en . "Christian Berger, \"Process for preparing levomepromazine hydrogen maleate.\" U.S. Patent US4798895, issued January 17, 1989."@en . "A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)"@en . . "Levomepromazinum"@en . . "Take with food to reduce irritation."@en . . . . . . . . "Approximately 20 hours."@en . "2-Methoxytrimeprazine"@en . . . . . . . . . . "For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder."@en . .